Akebia Therapeutics Marks Major Milestones with Vafseo Launch and New Trials Akebia Therapeutics announces significant progress regarding Vafseo, including new commercial contracts and upcoming clinical trials aimed at expanding treatment options.

Akebia Therapeutics Marks Major Milestones with Vafseo Launch and New Trials #United_States #Cambridge #Vafseo #Akebia_Therapeutics #CKD

Akebia Therapeutics Announces Presentation Plans for the 43rd J.P. Morgan Healthcare Conference Akebia Therapeutics will present at the J.P. Morgan Healthcare Conference, discussing the U.S. launch of Vafseo and business updates on January 16, 2024.

Akebia Therapeutics Announces Presentation Plans for the 43rd J.P. Morgan Healthcare Conference #United_States #Cambridge #J.P._Morgan #Vafseo #Akebia_Therapeutics

NICE recommends vadadustat for anaemia during dialysis for chronic kidney disease Vadadustat (Vafseo; Medice) has been recommended for symptomatic anaemia in adults undergoing dialysis for chronic kidney disease (CKD) by the National Institute for Health and Care Excellence…

Draft guidance from the National Institute for Health and Care Excellence has recommended vadadustat for symptomatic anaemia in adults undergoing dialysis for chronic kidney disease

#CKD #vafseo #medice

U.S. Renal Care Begins Enrollment for VOICE Trial Evaluating Vafseo® Outcomes in CKD Dialysis Patients The VOICE trial, initiated by U.S. Renal Care, starts evaluating Vafseo® for treating anemia in dialysis patients, aiming for market launch in 2025.

U.S. Renal Care Begins Enrollment for VOICE Trial Evaluating Vafseo® Outcomes in CKD Dialysis Patients #United_States #Cambridge #Vafseo #Akebia_Therapeutics #CKD_dialysis